News

We are pleased to announce that our Eysins site in Switzerland has successfully passed the annual ISO 14001 Surveillance Audit. This site, first certified in 2022, continues to demonstrate our commitment to environmental management and sustainability. The ISO 14001 is an internationally recognized standard for environmental management systems (EMS). This certification reaffirms the Eysins site’s…

AliveDx Suisse S.A. and Palex Medical S.A.U. have signed a distribution agreement, which will enable Palex to distribute the MosaiQ® solution in Spain. The distribution agreement takes effect immediately. This partnership reaffirms AliveDx’s commitment to expanding its geographical presence and creating clinical and economical value for clinicians, helping them to shorten the time to diagnosis.…

AliveDx Suisse S.A. and Medical Development Medical Devices WLL have signed a distribution agreement, which will enable Medical Development Medical Devices to distribute the MosaiQ® solution in the Kingdom of Bahrain. The distribution agreement takes effect immediately. AliveDx is dedicated to expanding its reach and presence across various regions. This strategic collaboration with a solid…

AliveDx Suisse S.A. and Lavichem Joint Stock Company have signed a distribution agreement, which will enable Lavichem to distribute the MosaiQ® solution in North Vietnam. The distribution agreement takes effect immediately. AliveDx is committed to broadening its reach and presence across different regions, aiming to generate both clinical and economical value for clinicians, helping them…

AliveDx Suisse S.A. and Medlinks Consulting Joint Stock Company have signed a distribution agreement, which will enable Medlinks to distribute the MosaiQ® solution in South Vietnam. The distribution agreement takes effect immediately. AliveDx is dedicated to expanding its reach and presence across various regions and to creating clinical and economical value for clinicians, helping them…

We are excited to announce that our abstract titled “Performance characteristics of a novel, fully automated immunoassay microarray for the qualitative serological detection of specific IgE directed against Bet v 1” has been accepted by the European Congress of Immunology (ECI 2024), a major international event on immunology, to be held in Dublin, Ireland, from…

AliveDx Suisse S.A. and Patho Solutions Malaysia Sdn. Bhd. have signed a distribution agreement, which will enable Patho Solutions Malaysia to distribute the MosaiQ® solution in Malaysia. The distribution agreement takes effect immediately. AliveDx is dedicated to expanding its reach and presence across various regions and to creating clinical and economical value for clinicians, helping…

AliveDx Suisse S.A. and Everlight Biotech Co. Ltd. have signed a distribution agreement, which will enable Everlight Biotech Co. Ltd. to distribute the MosaiQ® solution in Taiwan. The distribution agreement takes effect immediately. AliveDx is dedicated to expanding its reach and presence across various regions. This strategic collaboration with a prominent partner in Taiwan underscores…

At AliveDx, we understand that the success of our business is closely linked to the wellbeing of the communities in which we operate. Our goal is to advance sustainable practices in every aspect of our operations. We are pleased to present the AliveDx 2023 Sustainability Report as a testament to our dedication. The 2023 Sustainability…

AliveDx Suisse S.A. and Ozgun Kimya A.S. have signed a distribution agreement, which will enable Ozgun Kimya A.S. to distribute the MosaiQ® solution in Türkiye. The distribution agreement takes effect immediately. This strategic partnership reaffirms AliveDx’s consistent commitment to grow and expand its geographical presence. It will enable both parties to introduce new quality services…